JLE

Innovations & Thérapeutiques en Oncologie

MENU

Outcome of cancer patients infected with Covid-19 at the Ion Chiricuţă Institute of Oncology in Cluj, Romania Volume 6, issue 3-4, May-August 2020

Authors
1 Institut de cancérologie Prof. Dr. Ion Chiricuţă
34-36, rue de la République
400015 Cluj-Napoca
Roumanie
2 Université de médecine et pharmacie Iuliu Haţieganu
8, rue Victor Babeş
400000 Cluj-Napoca
Roumanie
3 Hôpital clinique de maladies infectieuses
23, rue Iuliu Moldovan
Cluj-Napoca
Roumanie
* Tirés à part

The seriousness of the association between Covid-19 and cancer remains a controversial topic. Between April and June 2020 at the Institute of Oncology in Cluj, 44 patients presented with a positive RT-PCR test. During the infection, 31.8% remained asymptomatic, 15.9 developed a mild form, 31.8% had a moderate form, and 11.4% a severe form of Covid-19 that led to death. Male sex and advanced active cancer were the only negative prognostic factors based on the univariate analysis. Treatment included hydroxychloroquine (23/40; 57.5%), anticoagulants (21/40; 52.5%), paracetamol (19/40; 47.5%), lopinavir/ritonavir (18/40; 45%), and azithromycin (17/40; 42.5%). In our series, the incidence of Covid-19 infection was similar between cancer patients and the general population and the difference in death rate was also not statistically significant (11.4% vs 4.9%; p = 0.11). With active testing, we are attempting to keep the institute coronavirus-free.